Evidence map›Paper›PMID 42196460›Full record

ReviewInternational journal of molecular sciences2026

Dynamic Time-Resolved Remodeling of the Immune Microenvironment After Resistance to BRAF/MEK Inhibitors in Melanoma: Mechanisms, Biomarkers, and Emerging Therapeutic Strategies.

Wenjun Meng, Yan Liu, Haoran Zhang, Manting Wang, Xiaoli Mu, Ziqi Zhang, Yan Tie

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Wenjun MengDepartment of Pain Management, West China Hospital, Sichuan University, Chengdu 610041, China.ORCID 0000-0002-6780-8720
Yan LiuOutpatient Department, West China Hospital, Sichuan University, Chengdu 610041, China.
Haoran ZhangWest China School of Medicine, Sichuan University, Chengdu 610041, China.
Manting WangWest China School of Medicine, Sichuan University, Chengdu 610041, China.
Xiaoli MuHealth Management Center, General Practice Medical Center, West China Hospital, Sichuan University, Chengdu 610041, China.
Ziqi ZhangDepartment of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu 610041, China.
Yan TieDepartment of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu 610041, China.

Funding

National Natural Science Foundation of China 82403597Natural Science Foundation of Sichuan Province 2026NSFSC0685
6 · The paper itself

Abstract

Targeted inhibition of the MAPK pathway with BRAF and MEK inhibitors (BRAFi/MEKi) produces rapid tumor regressions in BRAF V600-mutant melanoma, yet most patients ultimately develop acquired resistance. Resistance is not solely a tumor-cell-intrinsic phenomenon; it is accompanied by time-dependent remodeling of the tumor immune microenvironment (TIME) that can shape sensitivity to immune checkpoint inhibitors (ICIs) and inform rational combination or sequencing strategies. Early during MAPK inhibition, melanomas often display increased melanoma antigen expression and enhanced CD8

Indexed as

Drug Resistance, NeoplasmMelanomaProtein Kinase InhibitorsProto-Oncogene Proteins B-rafTumor MicroenvironmentAnimalsBiomarkers, TumorHumansImmunotherapyBiomarkers, TumorBRAF protein, humanProtein Kinase InhibitorsProto-Oncogene Proteins B-rafacquired resistanceBRAF inhibitorimmune escapeMEK inhibitormelanomatumor immune microenvironment

Identifiers

PMID42196460
PMCPMC13207537

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.